Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study by Trinacty, Connie M et al.
BioMed CentralBMC Health Services Research
ssOpen AcceResearch article
Racial differences in long-term adherence to oral antidiabetic drug 
therapy: a longitudinal cohort study
Connie M Trinacty*1, Alyce S Adams1,2, Stephen B Soumerai1, Fang Zhang1, 
James B Meigs3, John D Piette4 and Dennis Ross-Degnan1
Address: 1Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA, 2Division 
of Research, Kaiser Permanente Northern California, Oakland, CA, USA, 3General Medicine Unit, Department of Medicine, Massachusetts General 
Hospital and Harvard Medical School, Boston, MA, USA and 4VA Center for Clinical Management Research and Division of General Medicine, 
University of Michigan Health Care System, Ann Arbor, MI, USA
Email: Connie M Trinacty* - connie_trinacty@hphc.org; Alyce S Adams - alyce.s.adams@nsmtp.kp.org; 
Stephen B Soumerai - ssoumerai@hms.harvard.edu; Fang Zhang - fang_zhang@hphc.org; James B Meigs - jmeigs@partners.org; 
John D Piette - jpiette@umich.edu; Dennis Ross-Degnan - drossdeg@hms.harvard.edu
* Corresponding author    
Abstract
Background: Adherence to oral antidiabetic medications is often suboptimal. Adherence
differences may contribute to health disparities for black diabetes patients, including higher
microvascular event rates, greater complication-related disability, and earlier mortality.
Methods: In this longitudinal retrospective cohort study, we used 10 years of patient-level claims
and electronic medical record data (1/1/1992–12/31/2001) to assess differences in short- and long-
term adherence to oral antidiabetic medication among 1906 newly diagnosed adults with diabetes
(26% black, 74% white) in a managed care setting in which all members have prescription drug
coverage. Four main outcome measures included: (1) time from diabetes diagnosis until first
prescription of oral antidiabetic medication; (2) primary adherence (time from first prescription to
prescription fill); (3) time until discontinuation of oral antidiabetic medication from first
prescription; and (4) long-term adherence (amount dispensed versus amount prescribed) over a
24-month follow-up from first oral antidiabetic medication prescription.
Results: Black patients were as likely as whites to initiate oral therapy and fill their first
prescription, but experienced higher rates of medication discontinuation (HR: 1.8, 95% CI: 1.2, 2.7)
and were less adherent over time. These black-white differences increased over the first six
months of therapy but stabilized thereafter for patients who initiated on sulfonylureas. Significant
black-white differences in adherence levels were constant throughout follow-up for patients
initiated on metformin therapy.
Conclusion: Racial differences in adherence to oral antidiabetic drug therapy persist even with
equal access to medication. Early and continued emphasis on adherence from initiation of therapy
may reduce persistent racial differences in medication use and clinical outcomes.
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Diabetes is a leading cause of death and disability in the
United States, costing an estimated $174 billion in lost
productivity and health care expenditures each year. [1]
Black diabetes patients experience higher rates of microv-
ascular events, greater complication-related disability, and
nearly 30% higher mortality than white diabetes patients.
[2,3] Landmark randomized clinical trials have demon-
strated that intensive drug therapy can improve glycemic
control, reduce risk of microvascular and other diabetes-
related complications, and reduce overall health care
costs. [4-7] Yet, despite the proven benefits of adhering to
a prescribed medication regimen, many patients fall short
of adherence targets. [8-11]
Racial differences in medication adherence may reflect
disparities in other components of diabetes care such as
patient education and counseling, insurance coverage,
and geographic access to health care services. [12-16] In
previous studies, we found that blacks have higher glyc-
emic levels [17] and worse adherence to glucose self-mon-
itoring practice [18,19] even in a setting where variations
in the quality of care and insurance coverage have been
minimized. Evidence regarding the role of race in predict-
ing adherence to diabetes medications over time has been
limited to studies with small sample sizes, too few black
patients, and inadequate research designs to assess self-
care behavior (e.g., the use of self-report adherence meas-
ures). [12-14,20,21] In this longitudinal study, using ten
years of clinical and pharmacy claims data and a repeated
measures design, we examine the relationship between
race and both short- and long-term adherence to medica-
tion use among patients newly prescribed an oral antidia-
betic drug therapy in an HMO serving a large population
of both black and white patients with diabetes.
The purpose of this study was to determine whether racial
differences in short-term and long-term adherence exist in
this setting where a strong focus is placed on preventive
services, coordination of care, and standardization of serv-
ices and where other possible determinants of suboptimal
adherences to medication have been reduced, including
economic barriers in access to care. Given our previous
findings that racial differences in glycemic control and
self-monitoring of blood glucose exist and persist in spite
of equal access to services and treatment quality, we
expected to find similar race-related differences in medica-
tion adherence, with blacks hypothesized to be consist-
ently less adherent to prescribed regimens than whites
over time.
Methods
Study setting and data sources
Harvard Vanguard Medical Associates (HVMA) is a large
multi-specialty care group comprised of 14 health centers
serving over 300,000 people of diverse ethnic and socioe-
conomic backgrounds in the Boston area. Using HVMA's
electronic medical record system, we captured patient-
level data from 1992–2001 from all ambulatory and inpa-
tient encounters, including pharmacy encounters and lab-
oratory test results, diagnoses, procedures, and therapies.
The electronic medical record system also contained data
on a patient's date of birth, gender, months of member-
ship, and census tract of residence (which was linked to
socioeconomic characteristics of the neighborhood such
as income and education using the 1990 census files). In
addition, all records for emergency room visits, hospitali-
zations, and other services received outside the HVMA sys-
tem were recorded in a linked claims database.
Prescriptions for oral antidiabetic medications were
extracted from HVMA electronic ambulatory encounters
and linked to corresponding pharmacy medication dis-
pensing claims data. Previous studies have documented
the reliability of these longitudinal data. [22,23]
Study population
To be included in the study, patients had to be at least 18
years old, of black or white race, and newly diagnosed
with diabetes. Race, the key independent variable, was
determined from clinician reports. Although information
on race was not uniformly collected, a study comparing
self-reported and medical record data on race classifica-
tion found a 96% agreement (unpublished data). Patients
were classified as newly diagnosed based on a record of ≥
1 inpatient diagnosis of diabetes [ICD-9 codes 250.XX] or
≥ 2 outpatient diabetes diagnoses, or ≥ 1 prescription or
dispensing of insulin or oral antidiabetic medication (i.e.,
first or second generation sulfonylureas, metformin, meg-
litinides, thiazolidinedione, and alpha-glucosidase inhib-
itors), with no previous record of a diabetes diagnosis or
medication. Patients had to be continuously enrolled
(with no more than 45 days of disenrollment) in HVMA
and insured with Harvard Pilgrim Health Care (HPHC)
for at least one year prior to and one year after the first pre-
scription of oral antidiabetic medication.
Due to the difficulty in measuring insulin adherence
because of the wide variation of insulin dosages across
patients, adherence measures for patients on insulin treat-
ment were not developed. Patients who were prescribed
or dispensed an insulin therapy at any point in the follow-
up period were excluded from the study cohort. We also
excluded patients with a diagnosis of polycystic ovarian
syndrome (who may sometimes be prescribed an oral
anti-diabetic agent) unless they also received a diabetes
diagnosis. Any patient with a diagnosis of gestational dia-
betes during the observation period was also excluded.
Since less than 1% of all study patients initiated therapy
on meglatinide, thiazolidinedione, or alpha-glucosidase
inhibitors, we excluded them in the main analyses andPage 2 of 10
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apy was sulfonylurea or metformin. The resulting study
sample consisted of 1906 patients.
Measures
Patterns of medication use
We used four outcome measures to capture patients' pat-
terns of medication use. First, we examined the time from
diabetes diagnosis until the first prescription for oral anti-
diabetic medication. Second, among those with prescrip-
tions, we examined primary adherence by measuring the
time from first prescription for an oral antidiabetic drug
until the patient filled the prescription. Third, we meas-
ured the time between first prescription and discontinua-
tion of medication therapy (= 60 days without a refill
following last day without medication). Lastly, we exam-
ined long-term adherence, defined as the monthly average
rate of adherence, comparing dose available in each
month through prior dispensings in relation to dose pre-
scribed in each month over a 24-month follow-up from
time of first prescription. To construct these adherence
measures, we assessed refill-based medication adherence
linking prescribing information from clinical encounter
data and pharmacy claims for dispensed data. Standard
refill-based medication adherence measures assume that
days supply is equivalent to daily dose and, therefore, can-
not distinguish between physician initiated changes in
therapy and patient noncompliance. [24,25] Our measure
is based on actual daily dose information from prescrib-
ing notes to determine intended daily dose. These then
were linked to dispensed oral antidiabetic medication
information which was allocated in daily amounts
according to the most recent prescription until the supply
was exhausted. A patient was considered to have discon-
tinued therapy once 60 days had elapsed without any oral
antidiabetic medication available. Patients had a strong
financial incentive (e.g., smaller copayments) to fill pre-
scriptions within the health care setting under study.
Median co-payment levels for the most commonly used
diabetes drugs were similar for blacks and whites (e.g.,
glyburide: median copay = $10). For each oral antidia-
betic medication, a time-varying adherence measure was
calculated as the milligrams dispensed divided by the
amount prescribed per month to obtain a percentage of
the prescribed among that was available for use. For
patients taking more than one oral medication during fol-
low-up, we calculated the combined average adherence
per month.
Covariates
Our covariates were comprised of both baseline (defined
as 12 months prior to the beginning of a patient's medica-
tion treatment) and time-varying covariates. Baseline cov-
ariates included gender, age, census block group-derived
median neighborhood household income and average
educational attainment level, body mass index (BMI), and
average HbA1c level over the prior year. For time-varying
covariates, we used a previously validated method [26] to
calculate the presence and number of comorbidities per
month by counting the number of non-diabetes medi-
cines taken by each patient using the first eight digits of
the American Hospital Formulary Services (AHFS) code.
We also included as a control for severity of illness a
monthly indicator of whether the patient had a diabetes-
related hospitalization or emergency room visit (ICD-9 =
250.XX). To adjust for differences in patient involvement
with the care system, we controlled for number of outpa-
tient physician visits per month.
Statistical analysis
We performed all statistical analyses using SAS V8.02
(Cary, NC SAS, Inc 2000). [27] Chi-square and t-test sta-
tistics were used to test race differences in demographic,
clinical and utilization characteristics in the 12 months
prior to first prescription of diabetes medication. Bivariate
correlates of race (p < 0.2) were included as covariates in
multivariate analyses.
Given the clinical differences in side-effects between sul-
fonylurea and metformin and the greater likelihood in
discontinuation of metformin therapy due to its side-
effects, we stratified all analyses by these two most com-
monly prescribed oral therapy groups. Patients on a com-
bination of metformin and other oral antidiabetic
medication were represented in the metformin group.
We conducted survival analyses to examine racial differ-
ences in the time to initiation and discontinuation of oral
antidiabetic drug therapy. Within the oral antidiabetic
drug therapy initiators, we produced unadjusted cumula-
tive probability curves of time to first prescription since
diagnosis, time to filling this first prescription, and time to
discontinuation of medication use, all stratified by race.
We fit Cox survival regression models, [27,28] with both
fixed and time-dependent covariates, to estimate the haz-
ard rate of blacks relative to whites for both initiation and
discontinuation of oral antidiabetic medication. Patients
were censored at the end of continuous enrollment or end
of the 24-month follow-up.
For our final multivariate analyses, we estimated the effect
of race on long-term adherence among patients for 24
months, allowing patients who discontinued use for more
than 60 days but reinitiated therapy thereafter to contrib-
ute to these analyses. We excluded patients with fewer
than 24 months of follow-up from the time of first pre-
scription or who switched or augmented medication ther-
apy with insulin during the 24-month follow-up. The
resulting analytical sample for the adherence analyses
included 1404 patients. Within therapy groups, we usedPage 3 of 10
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estimate and test the difference in mean adherence rates
for the two race groups at eight quarterly time intervals. In
these models, we controlled for key demographic and
clinical covariates as well as clinical sites serving dispro-
portionately high numbers of black patients. Quarterly
intervals were included in the model as dummy terms
(with the initiation month of drug treatment as a refer-
ent). To test whether race differences varied across quar-
ters, we used likelihood ratio tests. We also stratified these
analyses by pre-treatment HbA1c group (average HbA1c
levels >9.0%; between 7.0% and 9.0%; <7.0%) [29] to
adjust for race differences in severity of diabetes prior to
initiation of oral antidiabetic medication. This study was
approved by the HPHC Institutional Review Board.
Results
Description of study cohort
As shown in Table 1, 74% of the 1906 patients in the ana-
lytic sample were white and 26% were black. Black
patients were more likely to be female, younger, and to
have poorer glycemic control at baseline, but had fewer
non-diabetes medications prior to receiving their first pre-
scription of oral antidiabetic drug therapy. Most patients
started glucose self-monitoring within the 12 months
prior to initiating an oral antidiabetic drug therapy, with
more blacks initiating than whites. For both race groups,
the majority of patients were prescribed a sulfonylurea as
their first form of oral antidiabetic medication treatment.
Effects of race on oral antidiabetic medication use over 
time
Figure 1 shows race differences in cumulative rates of ini-
tiating an oral antidiabetic drug during 24 months follow-
ing first diabetes diagnosis, stratified by sulfonylurea and
metformin therapy groups. Among sulfonylurea therapy
patients, the unadjusted rate of initiation of medication
among blacks remained higher than among whites over
time. However, after adjusting for demographic and clini-
cal covariates, race no longer was a significant predictor of
initiation among sulfonylurea therapy patients (Hazard
Ratio, black versus white = 0.97, 95% Confidence Inter-
vals: 0.6, 1.5). There were no race differences in initiation
of medication among patients who were prescribed met-
formin as their initial therapy.
We found no black-white differences in primary adher-
ence to medication for either drug therapy group. Over
90% of black and white patients filled their first prescrip-
tion within 30 days. By the end of the 24-month follow-
up, nearly all patients had filled their prescription at least
once.
As shown in Figure 2, the cumulative rates of discontinu-
ation of therapy among newly prescribed oral antidiabetic
agent patients were consistently higher among blacks than
whites within both the sulfonylurea and metformin
groups. Substantial increases in medication discontinua-
tion and notable differences between blacks and whites
occurred by the end of the first six months of therapy
(34% blacks vs. 25% whites). Discontinuation of medica-
tion use steadily increased thereafter for both drug and
race groups, with fewer blacks continuing medication use
than whites. By the end of follow-up, more than half of
black patients had stopped medication use for more than
60 days, while 44% of whites had done so (p < 0.001).
Unadjusted rates of discontinuation were similar among
patients who received metformin. After controlling for key
covariates (Table 2), blacks taking sulfonylurea medica-
tions had a rate of discontinuation 1.8 times higher than
whites (95% CI: 1.2, 2.7). Blacks who initiated on a met-
formin medication had a rate of discontinuation 1.5 times
that of whites, but after adjustment, this difference was
not significant (95% CI: 0.4, 5.0).
Effects of race on long-term adherence to oral antidiabetic 
drug therapy
Figure 3 compares black and white differences in long-
term adherence to oral antidiabetic drug therapy during
24 months of follow-up. Levels of adherence were similar
between sulfonylurea-treated and metformin-treated
patients, with black-white differences in adherence appar-
ent in both drug therapy groups. Among sulfonylurea
therapy patients, both black and white patients showed
drops in adherence levels within three months of initial
medication therapy, with a more substantial decrease
occurring among black patients. Although likely
explained by high discontinuation rates of therapy by the
third month as shown in Figure 2, this racial gap remained
fairly constant thereafter; over time, blacks were taking on
average 50% of their prescribed monthly dose of oral anti-
diabetic medication compared to an average of 60% of
prescribed monthly dose among whites. Among the met-
formin therapy group, blacks were also consistently less
adherent to medication than whites, with substantial
drops occurring within three months of initiating medica-
tion for blacks and five months for whites.
After controlling for key covariates, blacks were consist-
ently less adherent to sulfonylurea medication than
whites, with significant black-white differences occurring
within the second quarter of follow-up (Incidence Rate
Ratio, blacks versus whites: 0.86; 95% CI: 0.78, 0.96,
Table 3). Race differences decreased in the third quarter
and remained relatively constant (IRR = 0.90–0.96) in
subsequent quarters. Among patients on metformin ther-
apy, there was a significant race difference in non-adher-
ence between blacks and whites across quarters (IRR,
blacks vs. whites: 0.79; 95% CI: 0.63, 0.99), but the mag-
nitude of this difference fluctuated somewhat over the fol-Page 4 of 10
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for race and quarter effects.
Discussion
In this longitudinal investigation of adherence to oral
antidiabetic medication in a large, fully insured HMO dia-
betes population, we found no racial differences in initia-
tion of treatment or in primary adherence (time until first
prescription filled) among newly diagnosed diabetes
patients. However, rates of discontinuation in medication
use varied by race, with blacks discontinuing sooner and
at higher rates than whites, particularly among patients
initiating sulfonylurea therapy. Re-initiation of therapy
after discontinuing for more than 60 days did not appear
to show a substantial increase in adherence levels for
either race group over time. In concordance with our
Table 1: Racial differences in baseline* demographic and clinical status of diabetes patients (N = 1906)
Black
N = 498 (26.1%)
White
N = 1408 (73.9%)
Demographic Characteristics
Male 49.4 57.2†
Mean Age (SD) 45(10) 53(13)†
Census-Derived SES Measures
Living in neighborhood with mean household income below poverty level 30.9 9.2†
Living in neighborhood where >75% residents do not understand spoken English 32.4 13.6†
Living in neighborhood where >75% residents do not have high school degree 5.6 0.8†
Health Service Utilization
Mean # of MD Visits (SD) 3(2) 3(2)
Mean # of Lab Tests (SD) 2(1) 2(1)
Clinical Characteristics
Glycemic Control§
Good (<7.0%) 35.7 41.1
Moderate (7.0%–9.0%) 44.4 45.4
Poor (>9.0%) 19.9 13.6
Mean HbA1c Values§ (SD) 7.8(1.6) 7.6(1.5)†
Body Mass Index (BMI)||
Overweight (30–<40) 42.6 48.6
Obese (40+) 16.0 13.6
Mean BMI|| (SD) 33.2(7.6) 32.8(6.6)
Comorbidities
Any Diabetes-Related Hospitalizations 8.6 10.8
Any Diabetes-Related ER Visits 9.4 9.2
Monthly Mean # AHFS¶ (SD) 1.9(0.9) 2.1(1.0)†
Self-Management Practice
Initiation of Self-Monitoring Blood Glucose 70.7 59.6†
Initiation of Medication Therapy
Sulfonylurea 86.7 85.8
Metformin (alone or in combination) 13.2 14.2
Data are expressed as % patients or mean (SD).
*Baseline = 12 months prior to first drug prescription, not including the month of first script.
†p <.05.
§ Among those with a baseline HbA1c test (% with HbA1c data = Black: 34.3%; White: 41.3%)
|| Among those with a baseline BMI (% with BMI data = Black: 49.0%; White: 52.1%).
¶AHFS = American Hospital Formulary Services.Page 5 of 10
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antidiabetic drug therapy than whites over time.
Our findings agree with previous studies reporting that
blacks have lower adherence to oral antidiabetic medica-
tion.[14] However, our longitudinal study is unique in
that we linked prescribing information to dispensing data
in order to build a more precise measure of daily and
monthly average adherence, which is important when
studying a population whose health status and medical
treatment change frequently. Furthermore, the use of mul-
tiple years of follow-up among a relatively large number
of fully insured, HMO population of black and white dia-
betes patients enabled us to identify when adherence lev-
els began to drop during the course of therapy, and when
levels of adherence for blacks and whites began to diverge.
The ability to identify time points when divergence with
respect to medication adherence occurs is important
information for clinicians working to support patients'
adherence over time and for developing more effective
system-level interventions.
While our findings demonstrate persistent racial differ-
ences in adherence levels for patients on sulfonylurea or
metformin therapies, racial differences in patterns of med-
ication use varied by drug therapy group. For those taking
sulfonylureas, the largest reductions in adherence and the
separation in adherence levels between black and whites
occurred early in treatment (quarter 2–3 following initia-
tion of therapy); racial differences appeared to decline
somewhat thereafter. This modest narrowing of race dif-
ferences over time may result from patients reinitiating
their medication therapy after early discontinuation.
Among metformin patients, race differences in adherence,
while somewhat inconsistent, appear to increase over
time. Additional research is needed to understand longi-
tudinal variations in adherence, timing of initiation of
insulin or re-initiation of oral antidiabetic drug use fol-
lowing discontinuation, and racial differences in these
behaviors.
In a recent study, [17] we found that even within a man-
aged care setting where equal access to services and high
quality of care are provided, some blacks still had poorer
glycemic control than whites. Our current study demon-
strates that adherence to oral antidiabetic drug therapy is
lower among blacks than whites, and suggest that these
persistent racial differences may account for part of the
Racial differences in cumulative initiation rates of prescribed oral antidiabetic therapy since first diabetes diagnosisFigure 1
Racial differences in cumulative initiation rates of prescribed oral antidiabetic therapy since first diabetes diag-
nosis. Month 0 = Month of first diabetes diagnosis
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that previous study. However, other unmeasured patient-
level factors may help to explain these disparities in med-
ication adherence and diabetes outcomes. For example,
racial and ethnic minorities with diabetes may face greater
barriers to medication adherence due to lower socioeco-
nomic status, poorer health literacy, higher rates of dis-
trust of providers and the health care system, concerns
about the efficacy of medications or their side effects, cost-
related underuse, and other psychosocial factors. [12,13]
Racial differences in cumulative rates of medication discontinuation among newly prescribed oral antidiabetic therapy patientsFigure 2
Racial differences in cumulative rates of medication discontinuation among newly prescribed oral antidiabetic 
therapy patients. Month 0 = Month of first medication prescription. Discontinuation = ≥ 60 days without available medica-
tion based on prescribed days' supply dispensed.
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Table 2: Adjusted predictors of discontinuation of first antidiabetic drug therapy during a 24-month follow-up period
Sulfonylurea (N = 1640) Metformin (N = 266)
Variable Hazard Ratio 95% Confidence Interval Hazard Ratio 95% Confidence Interval
Black vs. White 1.8 1.2, 2.7†† 1.5 0.4, 5.0
Male vs. Female 1.14 0.8, 1.6 1.6 0.6, 4.9
Age 1.02 1.01, 1.04† 1.0 0.9, 1.0
Low Income 1.0 0.7, 1.5 3.3 0.9, 11.5
< High School Education 0.5 0.1, 1.9 1.0 0.07, 14.1
HbA1c 7.0–9.0 vs. <7.0§ 0.8 0.6, 1.3 0.4 0.05. 3.1
HbA1c > 9.0 vs. <7.0§ 1.01 0.5, 1.9 4.6 0.5, 42.2
BMI (time-variant) 1.001 1.0, 1.03 1.0 0.9, 1.1
# AHFS|| (time-variant) 0.9 0.8, 1.1 0.9 0.5, 1.7
# of MD Visits (time-variant) 1.0 0.8, 1.2 1.2 0.5, 2.5
Analysis adjusted for health centers with disproportionately high numbers of black patients
†p < .05; ††p < .01.
§Glycemic control based on baseline HbA1c levels.
|| AHFS = American Hospital Formulary Services Dispensed.Page 7 of 10
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Racial differences in long-term adherence among patients newly prescribed oral antidiabetic therapyFigure 3
Racial differences in long-term adherence among patients newly prescribed oral antidiabetic therapy. Month 0 
= Month of first medication prescription. Adherence (%) = (Total mgs available in month/Total mgs prescribed in month) * 
100%.
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Table 3: Racial differences in average adherence to oral antidiabetic medication over a 24-month follow-up period
Sulfonylurea (n = 1256) Metformin (n = 148)
Time Since First Prescription Incidence Rate Ratio 95% Confidence Interval Incidence Rate Ratio 95% Confidence Interval
Across All Quarters 
(Blacks vs. Whites)
0.96 0.89, 1.05 0.79 0.63, 0.99†
Within Quarters 
(Blacks vs. Whites)
Quarter 1 1.00 0.92,1.09 0.78 0.80, 1.00
Quarter 2 0.86 0.78, 0.96† 0.86 0.65, 1.13
Quarter 3 0.90 0.80, 1.00 0.92 0.69, 1.21
Quarter 4 0.91 0.81, 1.02 0.72 0.49, 1.06
Quarter 5 0.94 0.84, 1.05 0.63 0.41, 0.96†
Quarter 6 0.92 0.81, 1.03 0.83 0.59, 1.17
Quarter 7 0.92 0.81, 1.05 0.69 0.45, 1.06
Quarter 8 0.96 0.84, 1.04 0.59 0.35, 0.97†
Adjusted for age, gender, neighborhood socioeconomic status, body mass index, any HbA1c test, baseline glycemic level, number of MD visits, and 
number of comorbidities, health centers with disproportionately high numbers of black patients; Referent Group: initiation month of treatment 
group; All rates reflect both main effect of race and quarter effects.
†p < .05
BMC Health Services Research 2009, 9:24 http://www.biomedcentral.com/1472-6963/9/24We also did not examine other potential determinants
such as differences in regimen complexity, provider-
patient communication, clinical inertia, variations in pre-
scribing patterns, or provider perceptions about the bene-
fits of tight adherence.
This study has additional potential limitations worthy of
discussion. First, because race was determined from clini-
cian reports, misclassification may have occurred. How-
ever, assessments of white and black race from these
sources have been shown to be highly reliable. [22,23]
Race/ethnicity may also serve as a proxy for a myriad of
cultural and psychosocial factors that can influence
patient medication use. [30] A key advantage to our study
setting is that several potential race-related differences in
economic factors (e.g., comparable co-payments) and sys-
tem-based barriers to care (e.g., higher quality of care and
access to services) have been minimized. To better isolate
the effect of race and capture differences in some of the
cultural and psychosocial factors associated with medica-
tion use, we controlled for neighborhood educational
attainment and income, but we did not have measures of
other cultural and psychosocial factors that may be closely
correlated with race. Therefore, any racial differences
observed in our analyses may in part represent unmeas-
ured socio-cultural as well as biological constructs. [31]
We controlled for a number of other potentially race-
related barriers to adherence, such as the number of phy-
sician visits per month. However, by doing so, we may
have over-controlled for racial disparities, such that we
underestimate the effect of race on adherence. For exam-
ple, if differences in adherence are due to blacks' use of
fewer services or receipt of less patient education, control-
ling for those factors may reduce estimates of the impact
of race on adherence behavior. For future work, a focus on
the volume and nature of patient interactions with the
health care system may enable us to identify additional
determinants of racial disparities and avenues for inter-
vention.
The rates of missing data for HbA1c and BMI in Table 1
are high for this study setting. However, these high rates
are driven by our definition of the baseline period, which
does not include the month of the first prescription.
Therefore, the low rate of capture is an artifact of the study
design and not an indication of the quality of the data or
of the care this study setting provides.
The age of our data represents a decade when sulfonylu-
reas were prescribed over metformin as the first line of
treatment contrary to ADA recommendation. However,
over time, metformin has become more commonly pre-
scribed as the initial oral therapy over sulfonylureas, par-
ticularly among obese patients. While the rate of initiating
sulfonylureas and metformin reported in this study may
not represent the current prescribing behavior of provid-
ers, self-management guidelines have not changed since
our study data and the implications of these study find-
ings remain very relevant to current medical practice.
Finally, our findings are restricted to a single multi-spe-
cialty care group in Massachusetts. While we cannot gen-
eralize our findings to non-managed care settings, the
large proportion of black patients enrolled at HVMA
allows for comparison to other studies of racial/ethnic dif-
ferences in diabetes self-management in similar settings.
Conclusion
Racial differences in adherence to oral antidiabetic drug
therapy persist over time within a health system that pro-
vides uniform access to services and high quality of care
for diabetes patients. While differences do not appear in
initiation of medication, racial gaps are quickly evident in
discontinuation and adherence over time. Early and con-
tinued emphasis on sustaining medication use after initi-
ation of medication may lead to improved adherence to
antidiabetic medication. Aggressive, culturally-specific
promotion of adherence among blacks or implementa-
tion of a patient-centered approach to identify barriers to
adherence and provide self-care supports during early
treatment may potentially reduce persistent racial differ-
ences in self-management practice and clinical outcomes.
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